CV Sciences (CVSI) Shares Outstanding (2010 - 2026)
CV Sciences (CVSI) posted Shares Outstanding (Entity) of $193.5 million for Q1 2026, up 4.99% sequentially from $184.3 million in Q4 2025, and up 4.99% YoY from $184.3 million in Q1 2025.
CV Sciences (CVSI) Shares Outstanding (2010 - 2026) Analysis & Trends
CV Sciences has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $193.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 4.99% year-over-year to $193.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.5 million (up 4.99% YoY) and the FY2025 annual result came in at $184.3 million, changed 0.0% from the prior year.
- Shares Outstanding (Entity) improved to $193.5 million in Q1 2026 per CVSI's latest filing, from $184.3 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $193.5 million in Q1 2026 and troughed at $122.8 million in Q1 2022.
- A 5-year average of $166.5 million and a median of $163.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) surged 36.53% in 2022, then changed 0.0% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $152.1 million in 2022, then advanced by 6.29% to $161.7 million in 2023, then increased by 13.97% to $184.3 million in 2024, then changed by 0.0% to $184.3 million in 2025, then grew by 4.99% to $193.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $193.5 million, $184.3 million, and $184.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 832.44 Mn |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 205.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 205.09 Mn |
| Mar 31, 2026 | 186.92 Mn |
| Dec 31, 2025 | 184.26 Mn |
| Sep 30, 2025 | 184.26 Mn |
| Jun 30, 2025 | 184.26 Mn |
| Mar 31, 2025 | 184.26 Mn |
| Dec 31, 2024 | 175.59 Mn |
| Sep 30, 2024 | 182.26 Mn |
| Jun 30, 2024 | 172.42 Mn |
| Mar 31, 2024 | 163.08 Mn |
| Dec 31, 2023 | 153.95 Mn |
| Sep 30, 2023 | 154.60 Mn |
| Jun 30, 2023 | 152.60 Mn |
| Mar 31, 2023 | 152.10 Mn |
| Dec 31, 2022 | 138.03 Mn |
| Sep 30, 2022 | 146.53 Mn |
| Jun 30, 2022 | 135.41 Mn |
| Mar 31, 2022 | 116.83 Mn |
| Dec 31, 2021 | 107.82 Mn |
| Sep 30, 2021 | 109.12 Mn |